Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

30.80 -0.39 (-1.25%)
Delayed Quote Updated: 12:33 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes. 
Via MarketBeat
Topics Artificial Intelligence Bonds
News headline image
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? ↗
This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones ↗
Via Chartmill
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 ↗
This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid ongoing drug development milestones. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next ↗
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. ↗
This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a year of sharp share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions. 
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies. 
Via The Motley Fool
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
Via The Motley Fool
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment ↗
The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks. 
Via Stocktwits
News headline image
A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now ↗
General Atlantic is building its position just as Pharvaris nears pivotal readouts. This article breaks down what the fund may be anticipating and the signals investors should track next. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Gets Booted in Latest Fund Update ↗
Bain Capital sold its entire stake in Nuvalent stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Bain Capital completely exited its position in Disc Medicine stock during the third quarter 
Via The Motley Fool
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress ↗
Pharvaris NV (PHVS) reported a Q2 2025 loss of €0.83/share, missing estimates. Revenue was nil as R&D spend rose. Focus remains on Phase 3 trials for deucrictibant in HAE/AAE-C1INH, with key data... 
Via Chartmill
News headline image
PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024 ↗
PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
News headline image
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 ↗
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 ↗
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision ↗
The company is working on a treatment for swelling attacks associated with a genetic disease. 
Via Investor's Business Daily
News headline image
FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps ↗
Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.